Medigene AG: Medigene announces participation at five upcoming scientific and investor conferences

Planegg (pta006/25.08.2017/07:30 UTC+2) Medigene AG (FSE: MDG1, Prime Standard, TecDAX) today announced its participation at five upcoming scientific and investor conferences:

DVFA 15th SCC Small Cap Conference
Date: 5 - 6 September 2017
Location: Frankfurt, Germany
Dr. Thomas Taapken, CFO, will give an oral company presentation on 6 September at 1:30 pm.

CAR-TCR Summit 2017
Date: 5 - 8 September 2017
Location: Boston, USA
Dr. Markus Dangl, Senior Vice President Research & Pre-Clinical Development of Medigene, will give an oral presentation on 6 September at 2:25 pm on the topic: "An automated method for TCR isolation and initial characterization".

CRI-CIMT-EATI-AACR
Date: 6 - 9 September 2017
Location: Mainz, Germany
Scientists of Medigene will present three posters with research results during the conference on the following topics: neoantigen-specific TCRs, the PRAME-specific TRC for MDG1011 and immune monitoring of dendritic cell vaccines.

Baader Investment Conference
Date: 18 - 21 September 2017
Location: Munich, Germany
Dr. Thomas Taapken, CFO of Medigene, will hold a company presentation on 18 September at 3.30 pm.

Global Precision Medicine & Biomarkers Leaders Summit
Date: 21 - 22 September 2017
Location: Munich, Germany

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

For more information, please visit www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,
email: investor@medigene.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

(end)

Emitter:	Medigene AG Lochhamer Straße 11 82152 Planegg Germany
Contact Person:	Medigene PR/IR
Phone:	+49 89 200033-3301
E-Mail:	public.relations@medigene.com
Website:	www.medigene.de
ISIN(s):	DE000A1X3W00 (Share)
Stock Exchange(s):	Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Hannover, Munich, Stuttgart, Tradegate